{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:01:30Z","timestamp":1762344090091,"version":"build-2065373602"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Conventional ultrasonography (cUS) and contrast-enhanced ultrasonography (CEUS) are used to evaluate breast cancer tumors and axillary lymph nodes (ALN), by which the treatment strategy for breast cancer is determined. A breast tumor size discrepancy on CEUS compared with cUS is often observed, for which the reasons are unclear. We hypothesized that this discrepancy reflects the metastatic potential, and this study investigated the association between size discrepancies on cUS and CEUS in relation to ALN metastasis in breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study enrolled 259 patients who underwent surgery for breast cancer after preoperative cUS and CEUS examinations. Patients were grouped into a DISCR (i.e., tumor size discrepancy\u2009\u2265\u20094.0\u00a0mm between CEUS and cUS measurements) and non-DISCR group. The primary outcome was ALN metastasis, defined by pathological evaluation. Secondary outcomes were the 5-year recurrence-free survival rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were 94 patients in the DISCR and 165 in the non-DISCR groups. No tumor size differences measured by cUS were observed between two groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.82), whereas the DISCR group had a significantly higher rate of ALN metastasis (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Multivariate analyses showed a discrepancy of \u2265\u20094.0\u00a0mm was a risk for ALN metastasis (odds ratio: 5.838, 95% confidence interval [CI]: 2.408\u201314.155). The 5-year recurrence-free survival rate was lower in the DISCR (0.750, 95% CI: 0.632\u20130.868) than in the non-DISCR (0.924, 95% CI; 0.870\u20130.978) group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>An increase in contrast-enhanced ultrasonography tumor size is helpful for assessing axillary lymph node metastasis and prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-025-15167-9","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:57:05Z","timestamp":1762343825000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of breast tumor size discrepancy between contrast-enhanced and conventional ultrasonography on axillary node metastasis: a retrospective cohort study"],"prefix":"10.1186","volume":"25","author":[{"given":"Tomohiro","family":"Oshino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutsumi","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsunori","family":"Horie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satonori","family":"Tsuneta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuchika","family":"Hosoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohsuke","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"15167_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"15167_CR2","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s10549-007-9556-1","volume":"107","author":"I Soerjomataram","year":"2008","unstructured":"Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat. 2008;107:309\u201330.","journal-title":"Breast Cancer Res Treat"},{"key":"15167_CR3","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/01.sla.0000245472.47748.ec","volume":"245","author":"I Langer","year":"2007","unstructured":"Langer I, Guller U, Berclaz G, Koechli OR, Schaer G, Fehr MK, et al. Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients. Ann Surg. 2007;245:452\u201361.","journal-title":"Ann Surg"},{"key":"15167_CR4","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jamaoncol.2023.3759","volume":"9","author":"OD Gentilini","year":"2023","unstructured":"Gentilini OD, Botteri E, Sangalli C, Galimberti V, Porpiglia M, Agresti R, et al. Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial. JAMA Oncol. 2023;9:1557\u201364.","journal-title":"JAMA Oncol"},{"key":"15167_CR5","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.clbc.2019.01.013","volume":"19","author":"I Natsiopoulos","year":"2019","unstructured":"Natsiopoulos I, Intzes S, Liappis T, Zarampoukas K, Zarampoukas T, Zacharopoulou V, et al. Axillary lymph node tattooing and targeted axillary dissection in breast cancer patients who presented as cN\u2009+\u2009before neoadjuvant chemotherapy and became cN0 after treatment. Clin Breast Cancer. 2019;19:208\u201315.","journal-title":"Clin Breast Cancer"},{"key":"15167_CR6","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0427","volume":"25","author":"MA Marino","year":"2020","unstructured":"Marino MA, Avendano D, Zapata P, Riedl CC, Pinker K. Lymph node imaging in patients with primary breast cancer: concurrent diagnostic tools. Oncologist. 2020;25:e231\u201342.","journal-title":"Oncologist"},{"key":"15167_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15027-z","volume":"11","author":"X Zheng","year":"2020","unstructured":"Zheng X, Yao Z, Huang Y, Yu Y, Wang Y, Liu Y, et al. Deep learning radiomics can predict axillary lymph node status in early-stage breast cancer. Nat Commun. 2020;11:1236.","journal-title":"Nat Commun"},{"key":"15167_CR8","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1055\/a-1403-2400","volume":"42","author":"V Cantisani","year":"2021","unstructured":"Cantisani V, Di Leo N, David E, Clevert DA. Role of CEUS in vascular pathology. Ultraschallmed. 2021;42:348\u201366.","journal-title":"Ultraschallmed"},{"key":"15167_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.14366\/usg.19022","volume":"39","author":"V Rafailidis","year":"2020","unstructured":"Rafailidis V, Huang DY, Yusuf GT, Sidhu PS. General principles and overview of vascular contrast-enhanced ultrasonography. Ultrasonography. 2020;39:22\u201342.","journal-title":"Ultrasonography"},{"key":"15167_CR10","first-page":"6985","volume":"7","author":"Z Wang","year":"2014","unstructured":"Wang Z, Zhou Q, Liu J, Tang S, Liang X, Zhou Z, et al. Tumor size of breast invasive ductal cancer measured with contrast-enhanced ultrasound predicts regional lymph node metastasis and N stage. Int J Clin Exp Pathol. 2014;7:6985\u201391.","journal-title":"Int J Clin Exp Pathol"},{"key":"15167_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-90099-9","volume":"15","author":"T Oshino","year":"2025","unstructured":"Oshino T, Enda K, Shimizu H, Sato M, Nishida M, Kato F, et al. Artificial intelligence can extract important features for diagnosing axillary lymph node metastasis in early breast cancer using contrast-enhanced ultrasonography. Sci Rep. 2025;15:5648.","journal-title":"Sci Rep"},{"key":"15167_CR12","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1016\/j.ultrasmedbio.2007.06.002","volume":"33","author":"YX Jiang","year":"2007","unstructured":"Jiang YX, Liu H, Liu JB, Zhu QL, Sun Q, Chang XY. Breast tumor size assessment: comparison of conventional ultrasound and contrast-enhanced ultrasound. Ultrasound Med Biol. 2007;33:1873\u201381.","journal-title":"Ultrasound Med Biol"},{"key":"15167_CR13","doi-asserted-by":"crossref","unstructured":"Sanegre S, Eritja N, de Andrea C, Diaz-Martin J, Diaz-Lagares \u00c1, J\u00e1come MA, et al. Characterizing the invasive tumor front of aggressive uterine adenocarcinoma and leiomyosarcoma. Front Cell Dev Biol. 2021;9:670185.","DOI":"10.3389\/fcell.2021.670185"},{"key":"15167_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.mvr.2023.104555","volume":"149","author":"A Bhargava","year":"2023","unstructured":"Bhargava A, Popel AS, Pathak AP. Vascular phenotyping of the invasive front in breast cancer using a 3D angiogenesis atlas. Microvasc Res. 2023;149:104555.","journal-title":"Microvasc Res"},{"key":"15167_CR15","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s12282-011-0311-4","volume":"20","author":"T Fujisawa","year":"2013","unstructured":"Fujisawa T, Hirakata T, Yanagita Y, Iijima M, Horikoshi H, Takeuchi K, et al. The detection of pCR after PST by contrast-enhanced ultrasonography for breast cancer. Breast Cancer. 2013;20:75\u201382.","journal-title":"Breast Cancer"},{"key":"15167_CR16","unstructured":"D\u2019Orsi CJ, Sickles EA, Mendelson EB, Morris EA. ACR BI-RADS\u00ae Atlas, Breast Imaging Reporting and Data System. 5th ed. Reston, VA: American College of Radiology; 2013;128\u2009\u2013\u200931."},{"key":"15167_CR17","doi-asserted-by":"publisher","first-page":"e105517","DOI":"10.1371\/journal.pone.0105517","volume":"9","author":"X Xiao","year":"2014","unstructured":"Xiao X, Ou B, Yang H, Wu H, Luo B. Breast contrast-enhanced ultrasound: is a scoring system feasible? A preliminary study in China. PLoS ONE. 2014;9:e105517.","journal-title":"PLoS ONE"},{"key":"15167_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-62496-z","volume":"14","author":"Y Fu","year":"2024","unstructured":"Fu Y, Zhong J, Tan Y, Zheng T, Liu M, Wang G. Contrast-enhanced ultrasound for differentiating benign from malignant focal solid renal lesions in pediatric patients. Sci Rep. 2024;14:11409.","journal-title":"Sci Rep"},{"key":"15167_CR19","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10396-024-01502-3","volume":"51","author":"T Ito","year":"2024","unstructured":"Ito T, Komoike Y. Understanding the basics and clinical applications of contrast-enhanced ultrasound for breast lesions. J Med Ultrason (2001). 2024;51:563\u20136.","journal-title":"J Med Ultrason (2001)"},{"key":"15167_CR20","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1055\/a-0586-1107","volume":"39","author":"PS Sidhu","year":"2018","unstructured":"Sidhu PS, Cantisani V, Dietrich CF, Gilja OH, Saftoiu A, Bartels E, et al. The EFSUMB guidelines and recommendations for the clinical practice of contrast-enhanced ultrasound (CEUS) in non-hepatic applications: update 2017 (long version). Ultraschall Med. 2018;39:e2\u201344.","journal-title":"Ultraschall Med"},{"key":"15167_CR21","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1056\/NEJMoa2412063","volume":"392","author":"T Reimer","year":"2025","unstructured":"Reimer T, Stachs A, Veselinovic K, Kuhn T, Heil J, Polata S, et al. Axillary surgery in breast cancer - primary results of the INSEMA trial. N Engl J Med. 2025;392:1051\u201364.","journal-title":"N Engl J Med"},{"key":"15167_CR22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","volume":"377","author":"G von Minckwitz","year":"2017","unstructured":"von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377:122\u201331.","journal-title":"N Engl J Med"},{"key":"15167_CR23","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385:2336\u201347.","journal-title":"N Engl J Med"},{"key":"15167_CR24","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394\u2013405.","journal-title":"N Engl J Med"},{"key":"15167_CR25","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38:3987\u201398.","journal-title":"J Clin Oncol"},{"key":"15167_CR26","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/nature04872","volume":"441","author":"G Christofori","year":"2006","unstructured":"Christofori G. New signals from the invasive front. Nature. 2006;441:444\u201350.","journal-title":"Nature"},{"key":"15167_CR27","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41416-020-01149-0","volume":"124","author":"NM Novikov","year":"2021","unstructured":"Novikov NM, Zolotaryova SY, Gautreau AM, Denisov EV. Mutational drivers of cancer cell migration and invasion. Br J Cancer. 2021;124:102\u201314.","journal-title":"Br J Cancer"},{"key":"15167_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0134-x","volume":"5","author":"J Fares","year":"2020","unstructured":"Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Sig Transduct Target Ther. 2020;5:28.","journal-title":"Sig Transduct Target Ther"},{"key":"15167_CR29","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.1038\/s41388-020-01432-7","volume":"39","author":"Q Wei","year":"2020","unstructured":"Wei Q, Qian Y, Yu J, Wong CC. Metabolic rewiring in the promotion of cancer metastasis: mechanisms and therapeutic implications. Oncogene. 2020;39:6139\u201356.","journal-title":"Oncogene"},{"key":"15167_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100773","volume":"13","author":"D Ribatti","year":"2020","unstructured":"Ribatti D, Tamma R, Annese T. Epithelial-mesenchymal transition in cancer: a historical overview. Transl Oncol. 2020;13:100773.","journal-title":"Transl Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15167-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15167-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15167-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:57:07Z","timestamp":1762343827000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15167-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15167"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15167-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"24 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by Hokkaido University Certified Review Board (020\u20130392), and the requirement for written informed consent was waived with comprehensive consent for all medical research and opt-out. All studies were performed in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1718"}}